Key facts
- This page summarizes Daniella Mehalik's Form 4 filing for PSYCHEMEDICS CORP (PMDI).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 24 Jan 2024, 17:21.
Daniella Mehalik - 22 Jan 2024 Form 4 Insider Report for PSYCHEMEDICS CORP (PMDI)
- Reporting relationship
- Vice President - Finance
- Issuer ticker
- PMDI
- Reported as of
- 22 Jan 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 24 Jan 2024, 17:21:10 UTC
- Prior SEC filing
- 19 Dec 2023
- Source filing
- View source filing
- Reporting owner signature
- Patrick J. Kinney, Jr. as attorney-in-fact for Daniella Mehalik
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Daniella Mehalik filed Form 4 for PSYCHEMEDICS CORP (PMDI) on 24 Jan 2024.
Change
- Previous filing in this sequence was filed on 19 Dec 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PMD
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +35,000
- Change %
- Price
- $0.000000
- Shares after
- 35,000
- Date
- 22 Jan 2024
- Ownership
- Direct
- Underlying class
- Common Stock, $.005 Par Value
- Underlying amount
- 35,000
- Exercise price
- $3.40
- Footnotes
- F1
PMD
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +70,000
- Change %
- Price
- $0.000000
- Shares after
- 70,000
- Date
- 22 Jan 2024
- Ownership
- Direct
- Underlying class
- Common Stock, $.005 Par Value
- Underlying amount
- 70,000
- Exercise price
- $3.40
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The option becomes exercisable with respect to 50% of the shares on January 22, 2025 and with respect to the remaining 50% on January 22, 2026.
Footnote F2
The option becomes exercisable, if at all, in two 35,000 share increments. The first increment of 35,000 shares becomes exercisable at the time the weighted average daily price of Psychemedics common stock on the Nasdaq Stock Market during any consecutive 60 calendar day period ending on or before January 22, 2027 shall have exceeded $5.50. The second increment of 35,000 shares becomes exercisable at the time the weighted average daily price of Psychemedics common stock on the Nasdaq Stock Market during any consecutive 60 calendar day period ending on or before January 22, 2028 shall have exceeded $6.50.